Johnson & Johnson Looks To Sell Diagnostics Unit

HFA Padded
HFA Staff
Published on
Updated on
Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is readying financial information and legal forms in order to sell one of its diagnostics businesses. Dow Jones reported that the diversified healthcare company has JPMorgan Chase & Co (NYSE:JPM) advising it on the sale, and the business could fetch as much as $5 billion. Ortho Clinical Diagnostics, the business in question, works in two primary markets, screening for blood transfusions and clinical laboratories. The company’s guiding focus is the early detection of disease in patients. The company was formed in 1997 after a merger between two members of the Johnson & Johnson (NYSE:JNJ) family, Ortho…

This content is exclusively for paying members of Hedge Fund Alpha

Log In

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

HFA Padded

The post above is drafted by the collaboration of the Hedge Fund Alpha Team.